The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Ophthotech wins a $50M milestone from Novartis

Ophthotech says it won a $50 million enrollment milestone from Novartis for reaching a goal on its Phase III Fovista study for wet, age-related macular degeneration.

Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system

After initially leaving Novartis' meningitis B jab, Bexsero, off its national immunization program, the British government is now negotiating with the Swiss pharma over price--a series of events that's led a top Novartis Vaccines employee to tab the U.K. vaccination assessment system "flawed."

Novartis ready to start its engines for 'most exciting launch' in company history

Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.

Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug

Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.

Mylan, Momenta, Sandoz join assault on Teva's new-and-improved Copaxone

After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.

Novartis takes a cue from GSK, Biogen with wide-open spaces in new Aussie HQ

Did GlaxoSmithKline fuel a trend when it unveiled that open-concept, super-fluid new building in Philadelphia's Navy Yard? We've seen several new pharma developments take the same tack. And now, Novartis has gone the same way with its planned Australian HQ in Sydney.

Novartis CEO Jimenez shrugs off biosimilars in the short term

Swiss drugmaker Novartis last month became the first drugmaker to present the FDA with an application for a biosimilar, kicking off a new era in the U.S. that many believe will be a game changer for the industry. But from where CEO Joe Jimenez sits, it looks like no big deal for now.

Novartis CEO predicts a looming biosimilars boom

Novartis' big generics operation at Sandoz has been one of the leaders in the field of biosimilar development. So when the chief lays out a timetable on the adoption of these long-awaited knockoffs of some of the industry's biggest biologics, FierceBiotech listens.

Novartis exits tuberculosis space

Novartis is transferring its full tuberculosis research and development program to the nonprofit TB Alliance, according to a company statement.